Vagus nerve stimulation (VNS) is an established treatment of medically refractory partial-onset seizures. Recent data from an open-label multicenter pilot study also suggest a potential clinical usefulness in the acute and maintenance treatment of drug-resistant depressive disorder. Despite the fact that surgery is needed to implant the stimulating device, the option of long-term use largely devoid of severe side effects would give this treatment modality a privileged place in the management of drugresistant depression. However, definite therapeutic effects of clinical significance remain to be confirmed in large, placebocontrolled trials. Besides the potential clinical usefulness, VNS can be used as a research tool in epilepsy patients implanted for clinical reasons, allowing neurophysiologic investigations of the parasympathetic system and its interactions with other parts of the central nervous system.
attached to the vagus nerve, made accessible by an incision in the neck. Through a subcutaneous tunnel, the electrodes are linked to the pulse generator. The system delivers electrical impulses at frequencies between 1 and 30 Hz, at 0.25 to 3.5 mA, with a pulse width varying from 130 to 1000 microseconds at variable on-off times.
Vagus nerve stimulation has recently gained considerable interest as a potential treatment of relative drugresistant major depressive episodes after the publication of results of an open-label, multicenter pilot study involving 60 patients. Results of these investigations and of a 1-year follow-up of 30 patients are promising (1, 2) .
The first clinical application of VNS in humans, however, concerns the treatment of medically refractory seizures. VNS has been used in more than 16,000 patients for the treatment of epilepsy since 1988, when the first pilot studies began (3, 4) . The US Food and Drug Administration approved the NCP system in 1997 for management of medically refractory partial-onset seizures (5) . The first implant of an NCP system for treatment resistant depression was performed in 1998 at the Brain Stimulation Laboratory of the Medical University of South Carolina. In 2001, VNS was approved for a CE mark (indicating compliance with safety and environmental regulations) in the member countries of the European Union for treatment of adults with treatment-resistant or treatment-intolerant chronic or recurrent depression, including unipolar and bipolar depression (3, 6, 7) .
Considerable experience with the technique of VNS has been gained from its application as a treatment of drugrefractory epilepsy, including information about its mode of action, its clinical efficacy, its side effect profile, and technical and safety-related aspects.
The precise mechanism by which VNS suppresses seizures is not known. However, the electrical stimuli applied at the vagus nerve must influence the state of excitability of the brain. This effect is mediated by the vagus nerve, a nerve containing approximately 80% afferent nerve fibers.
The cell bodies of the afferent cells are in the nodose ganglion and project primarily to the nucleus tractus solitarius (NTS). Neurons of this nucleus project to numerous areas in the forebrain and the brainstem, including indirect projections into the locus ceruleus and diffuse connections to the cortex. Important structures thought to mediate antiepileptic effects receiving projections from the NTS include the amygdala and the thalamus. The cell bodies of the efferent fibers are located in the nucleus ambiguous and the dorsal motor nucleus of the vagus nerve. They provide innervations of the heart, aorta, lungs, gastrointestinal tract, and voluntary striated muscles of the larynx and pharynx (8, 9) . The heart rate is mostly influenced by the right vagal nerve (10) . The build-up of the different parts of the vagal system-afferent and efferent parts with their respective brainstem nuclei (NTS and nucleus ambiguous and the dorsal nucleus of the vagus nerve) and the asymmetric distribution of function with the right vagal nerve preferentially involved in the chronotropic regulation of the heart-has been explained in an evolution-based concept, the polyvagal theory (11) .
Vagus nerve stimulation clearly has effects on brain function. In 21 patients assessed at baseline and 3, 6, and 12 months after implantation of a VNS system, serial electroencephalographic (EEG) studies showed a progressive decrease in the number of spikes on EEG with time. In five patients who showed active spikes and wave activity on baseline EEGs, a progressive increase in the duration of spike-free intervals and a progressive decrease in the duration and frequency of spikes and wave activity was found over time (12) . Acute effects on brain activity were assessed in a blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (BOLD fMRI) study conducted in six adults with recurrent drug-resistant major depression. VNS applied 7 seconds at 20 Hz resulted in a bilateral activation in the frontal cortex, the hypothalamus, and the left globus pallidus. However, at 5 Hz stimulation, the level of activation did not reach statistical significance compared with baseline recordings without stimulation. Brain regions activated by hearing a tone were also greater when VNS was applied at 20 Hz than at 5 Hz. These findings suggest a frequency-dependent activity of VNS (13) .
Treatment efficacy was evaluated prospectively in patients with medically refractory partial-onset seizures who had completed a 3-month, double blind, low-stimulation, controlled multicenter study (E05) initiated by the manufacturer of the device. Efficacy was evaluated by comparing the change in total seizure frequency at 3-month and 12-month VNS treatment with a 3-month preimplantation baseline. The median seizure reductions at 3 and 12 months were 34% and 45%, respectively. Twenty percent of patients had a 75% or greater reduction in seizure frequency at 12 months. Similar results confirming the efficacy of VNS in the treatment of medically refractory epilepsy were found in several other studies. Side effects were generally mild and transient (3) .
Mortality was assessed in a 2-year extension of a study of mortality and sudden, unexpected, unexplained death in epilepsy in the cohort of patients receiving VNS for the treatment of epilepsy. One thousand eight hundred nineteen patients were followed for a total of 3,176 person-years from implantation. The rates for sudden, unexpected, unexplained death in epilepsy under VNS treatment were found to be similar to those reported from clinical trials with new drugs and cohorts of patients with severe epilepsy. An intriguing finding was that the rate of sudden, unexpected, unexplained death of 5.5 per 1000 person-years over the period of the first 2 years of treatment fell to 1.7 thereafter (14) .
Cardiac arrhythmias attributable to VNS in patients undergoing chronic stimulation have not been described. Isolated complications of VNS such as chronic diarrhea, Horner syndrome, posture-dependent stimulation of the phrenic nerve, worsening of pre-existing obstructive sleep apnea, and exacerbation of preimplantation dysphoric disorders and psychotic episodes with VNS-associated seizure reduction have been reported (3).
RATIONALE OF USING VAGUS NERVE STIMULATION TO TREAT DEPRESSION
Biologic treatments in depression have a long tradition, best illustrated by the use of electroconvulsive therapy (ECT), which was developed from the 1930s on. Its application improved constantly, and today it is considered one of the most efficient treatments in psychiatry, with an acceptable side effect profile compared with the severity of the symptoms of medically treatment-resistant major depression (15) .
Depression is indeed one of the most burdensome diseases with respect to its global impact on morbidity, mortality, and loss of quality of life. According to a study supported by the World Health Organization, unipolar major depression will rank at the second place of the leading causes of disability-adjusted life years worldwide in 2020, just behind ischemic heart disease (16). Studies of acute major depression generally show an approximately 50 to 60% response rate to a medical antidepressant treatment after 6 weeks (17). However, a large proportion of patients with depression do not improve substantially even after two treatment trials using antidepressant drugs of different classes for at least 6 weeks at a standard dose agreed on as being generally effective. ECT is considered to have acute efficacy even in drug-resistant depression, ranging higher than 80% (18). However, a major problem in the treatment of depression is relapse prevention. In a study completed by 62 patients, at least 50% of patients relapsed within the first year after ECT, and approximately 90% of these relapses occurred in the first 6 months (19) . In a recently published study, 24 weeks after an ECT course, 39% of patients relapsed with combined maintenance therapy of nortriptyline and lithium, 60% with nortriptyline alone, and 84% with placebo (20) . Relapse prevention after successful ECT might necessitate further maintenance ECT sessions (21) . A well-tolerated, efficacious long-term treatment in medically resistant depression is not yet available. VNS could offer a valuable treatment option because it has a good side effect profile, as assessed in the treatment of epilepsy (6) .
The hypothesis that VNS could be effective in treating depressive disorder was initially based on the following observations:
1. Improved mood and cognition were observed in epilepsy patients treated with VNS. 2. Drugs used to treat epilepsy, including carbamazepine, gabapentin, lamotrigine, and valproate, are also effectively used to treat mood disorders. VNS also is an effective treatment of epilepsy. 3. Positron emission tomography studies show that VNS affects the metabolism and thus the function of limbic structures in a way compatible with antidepressant function. 4. Neurochemical studies in animals and humans reveal that VNS alters concentrations of monoamines within the central nervous system. 5. The vagus nerve is anatomically linked to brain structures related to mood disorders (2, 7, 8) .
CLINICAL RESULTS IN PATIENTS SUFFERING FROM MAJOR DEPRESSION
To date, published data of VNS in depressed patients include one open-label, multicenter pilot study conducted in the United States. In this study, 30 patients were included and 30 patients were later added, of whom one patient had to be excluded from the study (2, 22) . Patients with a DSM-IV diagnosis of major depressive disorder or bipolar I or II disorder were included who suffered currently from a major depressive episode (MDE). The MDE had to be longer than 2 years in duration, or the patient had to have experienced at least four MDEs (the first 30 patients). Patients had to score at least 3 on the Antidepressant Treatment History Form, indicating that they had failed to respond to at least two medication trials during the current MDE, using different medication classes. It was required that no substantial clinical improvement was detected in a psychotherapy trial of at least 6 weeks. The Hamilton score on the 28-item scale had to be at least 20, and scores on the Global Assessment of Function scale had to be 50 at maximum. Those with bipolar disorder had to have resistance, intolerance, or a medical contraindication to lithium. Exclusion criteria included atypical or psychotic features in the current MDE; a history of schizophrenia, schizoaffective disorder, or other non-mood disorder psychosis; current rapid-cycling bipolar disorder; a current secondary diagnosis; or signs of delirium, dementia, amnesia, or other cognitive disorder; and clinically significant current suicidal intent. During the acute study (baseline period before VNS and 12-week period after the implantation), medication regimens were kept stable except that medication dosage could be decreased but not increased (22) .
In a follow-up study, the first 30 included patients were assessed until 9 months after the 3-month acute study. During this period, changes in psychotropic medication and VNS parameters were allowed. The response rate (defined as at least 50% reduction in baseline Hamilton rating) was 40% (12/30), and the remission rate (Hamilton rating score less than 10) increased from 17% (5/30) after the acutephase study to 29% (8/28) (1).
The most common adverse side events at 1 year postimplantation were voice alteration (21%) and dyspnea and neck pain (each 7%). No patient discontinued because of adverse events. However, one patient had the generator explanted because of lack of efficacy at 11 months after implantation. An episode of deep venous thrombophlebitis and one episode of hypomania resulted in hospitalizations and were judged by the investigators as possibly related to stimulation. One patient received ECT treatment with the NCP system implanted but switched off. No complications were reported (1) .
The effect of VNS on cognitive functions was assessed in 27 treatment-resistant depressed patients taking part in the studies cited. They were assessed with a neurocognitive test battery before and 10 weeks after the start of VNS. No deterioration in any of the neurocognitive measures was detected. Motor speed (finger tapping), performance of the digit symbol test, verbal fluency, logical reasoning, working memory, and response inhibition improved (22) .
DISCUSSION
Vagus nerve stimulation is an effective, safe, and welltolerated treatment in patients with long-standing, refractory partial-onset seizures, and may also be beneficial in other types of seizure. However, data indicate that the effect of VNS may be delayed as long as a year and that patients continue to improve during that time. Actually, few patients with medically resistant epilepsy become seizure-free. Problems arising during the implantation procedure are rare and manageable. VNS might not be recommended to patients with cardiac conduction disorder and with sleep apnea At present, preliminary results available concerning the efficacy of VNS as a treatment of medically resistant depression suggest acute and longer-term effectiveness. Besides efficacy, technical aspects need to be investigated, such as how to tailor individual treatment concerning stimulation frequency, strength, and duration. In a recent report, the threshold of eliciting a response in the vagus nerve by VNS was found to be age-dependent, with higher thresholds in young patients (12) . The establishment of predictive factors for treatment response to VNS is important, because this is an invasive treatment.
Results from the open-label American multicenter study (D01) involving 60 patients yielded the following variants as significant in univariate analysis: receiving ECT ever in lifetime, response to most recent ECT, number of unsuccessful antidepressant trials in the current major depressive episode, and number of unsuccessful antidepressant trial categories in the current major depressive episode. Of the 13 patients who had not responded to more than seven adequate antidepressant trials, none met response or remitter criteria. It appears that VNS as currently delivered is most effective in patients with moderate but not extreme levels of resistance to conventional antidepressant treatments (22) .
Compared with other treatment modalities, the cost profile of VNS could be beneficial, if effective maintenance therapy could be achieved with either a reduction in the use of concomitant medications or a reduction in other costs, such as hospitalization for depression relapses. However, in the treatment of drug-refractory epilepsy, a seizure-free state is rarely achieved, and VNS is mostly combined with antiepileptic drug maintenance therapy (7).
In conclusion, preliminary available data suggest a sustained antidepressant effect in moderately medically resistant major depression. If these findings can be confirmed, VNS could become a key treatment in depression. As a research tool, VNS suffers from its invasiveness. Implantation of an NCP system needs a clear indication. However, further insights into the mechanisms of its action in depression, epilepsy, and other neuropsychiatric disorders are expected.
